All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the EHA2021 Virtual Congress, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)?
Should pre-transplant MRD be used to guide treatment in AML?
Craddock begins by outlining the reasons for the increased use of allogeneic transplant and reviews data that discuss the exclusion criteria and benefits of transplant. He goes on to discuss how patient outcomes could be improved and the importance of post-transplant maintenance. Finally, he highlights the need to generate prospective data, referring to the ongoing studies COSI and AMADEUS.
1st NCRI AML academy meeting | The David Grimwade Memorial Lecture
Professor Charles Craddock introduced the David Grimwade Memorial Lecture at the 1st NCRI AML academy meeting, which was to be given by Professor Gert Ossenkoppele.
Charles Craddock | EBMT 2019 | Optimization of the graft-versus-leukemia effect
At the 45th Annual Meeting of the EBMT, Charles Craddock talks about optimizing the graft-versus-leukemia effect
Subscribe to get the best content related to AML delivered to your inbox